Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
Company announcement – No. 44 / 2024 Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Placebo-adjusted reductions…
Reliance Global Group Announces Enhanced Terms for Pending Spetner Acquisition
Cash required to close reduced by over $2 million Acquisition remains on track - anticipated to close in the second half of 2024 LAKEWOOD, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE)…
Complete Solar Raises $40.5 Million for SunPower Asset Acquisition
LEHI, Utah, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Complete Solar Holdings, Inc. d/b/a Complete Solar (“Complete Solar” or the “Company”) (Nasdaq: CSLR), a solar technology, services, and installation company, today…
Embrace Change Acquisition Corp. Receives Additional Staff Determination Notice from Nasdaq Related to Delayed Quarterly Report
SAN DIEGO, Sept. 07, 2024 (GLOBE NEWSWIRE) -- Embrace Change Acquisition Corp. (Nasdaq: EMCG, EMCGW, EMCGU, EMCGR) ("Embrace Change" or the "Company"), announced today that on September 5, 2024, it…
Elis to host a webcast as part of non-deal roadshow
Saint-Cloud, 8 September 2024 – Elis’ management opens tomorrow, Monday 9 September, a previously scheduled non-deal investor roadshow during which the company will discuss its business and strategy. As part…
Elis organise un webcast dans le cadre d’un non-deal roadshow
Saint-Cloud, le 8 septembre 2024 – La direction d'Elis entame demain, lundi 9 septembre, un non-deal roadshow, dont la tenue était précédemment prévue, au cours de laquelle la société discutera…
Nouvel engagement de financement d’un montant minimum net de 3 M€ dans la perspective de la validation du plan de continuation
Avertissement : La société SAFE SA (la « Société ») a mis en place un financement sous forme d’obligations convertibles en actions nouvelles ou existantes (OCEANE) avec Global Corporate Finance…
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
Abstract Released Today Highlights Favorable Safety Profile and Early Evidence of Monotherapy Anti-Tumor Activity Investor Webcast to be Held Friday, September 13, 2024 at 12:00 pm ET WATERTOWN, Mass., Sept.…
Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress
8 September 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress…
Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024
Oslo, September 9, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces the presentation of updated data analysis from the UV1 Phase II…